The Effects of Intranasal and Oral Administration of Oxytocin on Responses to Emotional Scenes

Healthy Clinical Trial

Official title:

Differential Modulation of Neural and Behavioral Responses to Emotional Scenes by Intranasal and Oral Oxytocin Administration in Healthy Men

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05532501
• Other study ID #: UESTC-neuSCAN-91
• Status: Recruiting
• Phase: N/A
• Start date: September 20, 2022
• Est. completion date: February 20, 2023

Study information

• Verified date: July 2022
• Source: University of Electronic Science and Technology of China
• Contact: Keith M Kendrick, PhD
• Phone: 86-28-61830811
• Email: k.kendrick.uestc[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will investigate whether oxytocin administered either intranasally or orally (lingual) (24 international units, IU) can differentially modulate men's neural and behavioral responses to emotional scenes using an implicit emotional paradigm.

Description:

Previous studies have reported that oxytocin administration intranasally and orally (spray on the tongue) can modulate neural and behavioral responses during processing of face emotions and can influence top-down attention to social stimuli. However, no research has directly compared the neural and behavioral effects of the two different administration routes on the processing of emotional scenes. In the current randomized, double-blind, between-subjects, placebo-controlled study, 160 healthy male subjects will be recruited and receive treatment either oxytocin (24IU, orally/intranasally) or placebo (orally/intranasally). Prior to treatment, all subjects will complete a number of questionnaires to control for potential group differences in potential confounders in terms of personality traits and mood, including: Beck Depression Inventory-II (BDI), Autism Spectrum Quotient (ASQ), Liebowitz Social Anxiety Scale (LSAS), State-Trait Anxiety Inventory (STAI), Childhood Trauma Questionnaire (CTQ), Interpersonal Reactivity Index (IRI). Additionally, the Positive and Negative Affect Schedule (PANAS) is administered before the treatment and before and after completing the implicit emotional scanning task to measure any changes in mood. Forty-five minutes after receiving treatment, subjects will be required to undergo and MRI scanning session including structural scans and resting-state fMRI followed by an implicit emotional scene processing task (picture source: Nencki affective picture system, including positive, neutral, and negative-valence social and non-social scenes). After fMRI scanning, subjects will be required to rate emotional stimuli presented during the scan on valence, intensity, and arousal using 1-9 point Self-Assessment Manikin (SAM) scales.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 160
• Est. completion date: February 20, 2023
• Est. primary completion date: December 20, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

• Healthy subjects without any past or present psychiatric or neurological disorders

Exclusion Criteria:

• 1. History of brain injury 2. Head trauma 3. Substance abuse 4. Medication

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Oral Oxytocin
Administer oxytocin (24 IU) orally, 6 individual 0.1 ml puffs (4 IU/0.1ml) on the tongue (lingual), one every 30 seconds
• Intranasal Oxytocin
Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0.1ml), three puffs per nostril one every 30 seconds
• Oral placebo
Administer placebo orally, 6 individual 0.1 ml puffs on the tongue (lingual), one every 30 seconds.
• Intranasal placebo
Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds

Locations

Country	Name	City	State
China	school of life science and technology, University of Electronic Science and Technology of China	Chengdu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
University of Electronic Science and Technology of China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Compare the effects of oxytocin on neural responses to emotional scenes between intranasal and oral administration routes.	Comparison of whole brain neural (fMRI scanning) activation differences between oral and intranasal oxytocin administration to emotional scenes will be performed using a mixed ANOVA with route (oral/intranasal), treatment (oxytocin/placebo) as between subject factors and valence of emotional scenes (positive/negative/neutral) as within-subject factor, post-hoc comparisons will be conducted to further disentangle the significant interactions observed after the mixed ANOVA.	45~70 minutes after treatment
Primary	Compare the effects of oxytocin on behavioral responses to emotional scenes between intranasal and oral administration routes.	Differences in behavioral ratings of valence (1-9 point Self-Assessmen-Manikin (SAM) scale, 1 means very negative, 9 means very positive, 5 means neutral), intensity (1-9 point SAM scale, 1 means mild, 9 means strong), and arousal (1-9 point SAM scale, 1 means not aroused at all, 9 means very aroused) of emotional scene stimuli between oral oxytocin and intranasal oxytocin groups will be examined using mixed ANOVAs, respectively.	70~90 minutes after treatment
Secondary	Compare the effect of oxytocin on neural functional connectivity during processing of emotional scenes between intranasal and oral administration routes.	Comparison of functional connectivity (fMRI scanning) differences between oral and intranasal oxytocin administration to emotional scenes by means of a mixed ANOVA with route (oral/intranasal), treatment (oxytocin/placebo) as between subject factors and emotional scene (positive/negative/neutral) as within-subject factor, post-hoc comparisons was conducted to further disentangle the significant interaction observed after mixed ANOVA.	45~70 minutes after treatment
Secondary	Correlations between neural activation and behavioral effects of intranasal or oral oxytocin during emotional scene processing.	Pearson correlation tests will be used to compute correlations between any significant neural and behavioral effects of treatment.	45~90 minutes after treatment
Secondary	Correlations between functional connectivity and behavioral effects of intranasal or oral oxytocin during emotional scene processing.	Pearson correlation tests will be used to compute correlations between any significant neural and behavioral effects of treatment.	45~90 minutes after treatment
Secondary	Comparison of effects of oxytocin on pre-task resting-state functional connectivity (rsfMRI) between intranasal and oral administration routes.	Comparisons of whole brain rsfMRI will be performed using an ANOVA with route (oral/intranasal) and treatment (oxytocin/placebo) as between-subject factors. Post-hoc comparisons will be used to disentangle significant interactions observed in the ANOVA.	45~70 minutes after treatment
Secondary	Mood changes assessed by the Positive Affect Negative Affect Schedule (PANAS) in all treatment groups during the experiment.	The Positive Affect Negative Affect Schedule measures both positive and negative mood in a person. The Positive Affect score ranges from 10-50, with higher scores representing higher levels of positive affect. The Negative Affect scores range from 10-50, with lower scores representing lower levels of negative affect. The differences in PANAS scores at each time-point between treatment groups will be analyzed using mixed ANOVAs.	0~70 minutes